AstraZeneca said in a statement on Tuesday. “Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing Covid-19.
With this first global regulatory filing, we are one step closer to providing an additional option to help protect against Covid-19 alongside vaccines.
We look forward to sharing AZD7442 data for the treatment of Covid-19 later this year," said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.
The AstraZeneca medicine was 77 per cent effective in preventing symptomatic Covid in a clinical trial that included patients with high-risk factors for severe infection.